MCID: NRL005
MIFTS: 61

Neurilemmoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neurilemmoma

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 53 59 44 15 73
Schwannoma 12 53 29 55 6 15
Benign Schwannoma 53 59 73
Peripheral Fibroblastoma 53 59
Neurilemoma 53 59
Psammomatous Schwannoma 12
Neurolemmoma 53

Characteristics:

Orphanet epidemiological data:

59
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3192
MeSH 44 D009442
NCIt 50 C3269
SNOMED-CT 68 985004
Orphanet 59 ORPHA252164
UMLS via Orphanet 74 C0027809 C0854906

Summaries for Neurilemmoma

NIH Rare Diseases : 53 A schwannoma is a tumor of the peripheral nervous system or nerve root. A schwannoma develops from cells called Schwann cells, a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant schwannoma). Symptoms of a schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), schwannomatosis, or Carney complex. People with these genetic disorders usually have more than one schwannoma. Schwannomas may be diagnosed using imaging studies. A biopsy may confirm the diagnosis. Treatment of benign schwannomas may involve surgery to remove the tumor. Treatment of malignant schwannomas may include both surgery and radiation therapy.

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to neurilemmoma of the fifth cranial nerve and neurofibromatosis, type iv, of riccardi. An important gene associated with Neurilemmoma is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are ERK Signaling and Cytoskeletal Signaling. The drugs Gentamicins and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and breast, and related phenotypes are facial palsy and hearing abnormality

Wikipedia : 76 A schwannoma is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
# Related Disease Score Top Affiliating Genes
1 neurilemmoma of the fifth cranial nerve 33.2 GFAP NF1 NF2 PRKAR1A
2 neurofibromatosis, type iv, of riccardi 33.1 KIT NF1 NF2 PDGFRA
3 neurofibromatosis, type ii 33.0 EZR MSN NF1 NF2
4 neurofibrosarcoma 32.5 NF1 NF2
5 neurofibromatosis, type i 32.5 KIT NF1 PDGFRA
6 neurilemmomatosis 32.2 NF1 NF2 PRKAR1A SMARCB1
7 intraneural perineurioma 32.1 NF1 S100B SOX10
8 malignant triton tumor 32.1 DES NF1 S100B
9 schwannomatosis 1 32.1 NF2 SMARCB1
10 cellular schwannoma 32.0 NF1 NF2 NGFR S100B SOX10
11 plexiform schwannoma 31.7 ENO2 GFAP KIT NF1 NF2 NGFR
12 malignant peripheral nerve sheath tumor 31.5 KIT NF1 NF2 PDGFRA S100B SMARCB1
13 gastrointestinal stromal tumor 30.8 DES ENO2 KIT NES NF1 PDGFRA
14 perineurioma 30.5 KIT S100B VIM
15 spinal meningioma 30.4 ENO2 NF1 NF2 SOX10
16 meningioma, familial 30.3 ENO2 GFAP NF1 NF2 SMARCB1
17 plexiform neurofibroma 30.3 NF1 NF2
18 neurofibroma 30.1 KIT NF1 NF2 PDGFRA S100B SOX10
19 leiomyoma 30.0 DES KIT VIM
20 desmoid tumor 30.0 KIT PDGFRA
21 pilocytic astrocytoma 29.9 GFAP NF1 SOX10
22 epithelioid malignant peripheral nerve sheath tumor 29.9 ENO2 NF1 S100B SMARCB1
23 cavernous hemangioma 29.8 KIT PDGFRA VIM
24 neuroma 29.8 ENO2 GFAP NF2 S100B SMARCB1
25 microcystic meningioma 29.8 ENO2 GFAP
26 pleomorphic adenoma 29.8 GFAP S100B VIM
27 monosomy 22 29.8 NF2 SMARCB1
28 hemangioblastoma 29.8 ENO2 EZR GFAP S100B
29 spindle cell sarcoma 29.7 DES NF2 S100B VIM
30 amelanotic melanoma 29.7 KIT S100B VIM
31 cerebellopontine angle tumor 29.7 GFAP NF2 SMARCB1
32 anaplastic ganglioglioma 29.6 GFAP NES
33 clear cell meningioma 29.6 GFAP VIM
34 benign ependymoma 29.6 ENO2 GFAP NF2
35 hemangiopericytoma, malignant 29.6 DES NGFR S100B VIM
36 angiolipoma 29.6 DES VIM
37 malignant granular cell myoblastoma 29.6 ENO2 SOX10
38 clear cell sarcoma 29.6 ENO2 KIT S100B
39 traumatic brain injury 29.6 ENO2 GFAP S100B
40 brain injury 29.6 ENO2 GFAP S100B
41 granular cell tumor 29.6 DES ENO2 GFAP S100B VIM
42 oligodendroglioma 29.5 ENO2 GFAP PDGFRA S100B SOX10
43 embryonal sarcoma 29.4 DES KIT S100B VIM
44 malignant spindle cell melanoma 29.3 KIT NF1 NGFR SOX10
45 cutaneous fibrous histiocytoma 29.3 DES S100B VIM
46 ependymoma 29.3 ENO2 GFAP NES NF2 S100B VIM
47 glomus tumor 29.3 DES ENO2 VIM
48 ganglioglioma 29.3 ENO2 GFAP NES S100B SMARCB1
49 sarcoma, synovial 29.3 DES KIT VIM
50 tanycytic ependymoma 29.2 GFAP NES NF2 SMARCB1

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

Human phenotypes related to Neurilemmoma:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 facial palsy 59 32 frequent (33%) Frequent (79-30%) HP:0010628
2 hearing abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0000364
3 vertigo 59 32 frequent (33%) Frequent (79-30%) HP:0002321
4 morphological abnormality of the central nervous system 59 32 occasional (7.5%) Occasional (29-5%) HP:0002011
5 intestinal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0200008
6 nasal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100582
7 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
8 abnormality of the adrenal glands 59 32 occasional (7.5%) Occasional (29-5%) HP:0000834
9 abnormality of the larynx 59 32 occasional (7.5%) Occasional (29-5%) HP:0001600
10 abnormality of the breast 59 32 occasional (7.5%) Occasional (29-5%) HP:0000769
11 acute episodes of neuropathic symptoms 59 32 occasional (7.5%) Occasional (29-5%) HP:0003489
12 vestibular schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0009588
13 peripheral schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0009593
14 abnormality of the twelfth cranial nerve 59 32 occasional (7.5%) Occasional (29-5%) HP:0010826
15 abnormality of peripheral nervous system electrophysiology 59 32 hallmark (90%) Very frequent (99-80%) HP:0030177
16 allodynia 59 32 frequent (33%) Frequent (79-30%) HP:0012533
17 scleral schwannoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0100011
18 pain 59 Occasional (29-5%)
19 abnormality of the cranial nerves 59 Very frequent (99-80%)
20 abnormality of the fibula 59 Occasional (29-5%)
21 abnormality of parotid gland 59 Occasional (29-5%)
22 abnormality of esophagus morphology 59 Occasional (29-5%)
23 abnormality of the temporal bone 59 Very frequent (99-80%)
24 schwannoma 59 Very frequent (99-80%)
25 neurofibrosarcoma 59 Excluded (0%)
26 abnormality of fibula morphology 32 occasional (7.5%) HP:0002991
27 abnormal parotid gland morphology 32 occasional (7.5%) HP:0000197
28 abnormal esophagus morphology 32 occasional (7.5%) HP:0002031
29 abnormal temporal bone morphology 32 hallmark (90%) HP:0009911

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.45 PDGFRA
2 Decreased viability GR00221-A-1 10.45 PDGFRA PRKAR1A SMARCB1 KIT NF1
3 Decreased viability GR00221-A-2 10.45 PRKAR1A SMARCB1 NF1
4 Decreased viability GR00221-A-3 10.45 NF2 PDGFRA PRKAR1A SMARCB1
5 Decreased viability GR00221-A-4 10.45 PDGFRA PRKAR1A NF1
6 Decreased viability GR00301-A 10.45 KIT
7 Decreased viability GR00381-A-1 10.45 SMARCB1
8 Decreased viability GR00402-S-2 10.45 NF2 PDGFRA PRKAR1A SMARCB1 KIT NF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 SMARCB1 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 SOX10 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 S100B VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 KIT S100B SMARCB1 SOX10 VIM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
38 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Neurilemmoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 DES ENO2 GFAP KIT NF1 NF2
2 cellular MP:0005384 10.3 DES ENO2 GFAP KIT NF1 NGFR
3 homeostasis/metabolism MP:0005376 10.27 DES GFAP KIT NF1 NF2 NGFR
4 growth/size/body region MP:0005378 10.25 ENO2 EZR GFAP KIT NF1 NF2
5 cardiovascular system MP:0005385 10.22 DES GFAP KIT NF1 NGFR PDGFRA
6 mortality/aging MP:0010768 10.21 DES EZR GFAP KIT NF1 NF2
7 digestive/alimentary MP:0005381 10.19 EZR GFAP KIT NF1 NGFR PDGFRA
8 immune system MP:0005387 10.18 EZR GFAP KIT NF1 NF2 NGFR
9 embryo MP:0005380 10.13 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
10 craniofacial MP:0005382 10.09 ENO2 KIT NF1 NF2 NGFR PDGFRA
11 integument MP:0010771 10.06 KIT NF1 NF2 NGFR PDGFRA PRKAR1A
12 muscle MP:0005369 10.06 DES GFAP KIT NF1 NGFR PDGFRA
13 nervous system MP:0003631 10.02 ENO2 GFAP KIT NF1 NF2 NGFR
14 neoplasm MP:0002006 9.91 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
15 normal MP:0002873 9.91 GFAP KIT MSN NF1 NGFR PDGFRA
16 respiratory system MP:0005388 9.61 ENO2 KIT NF1 NF2 NGFR PDGFRA
17 pigmentation MP:0001186 9.55 KIT NF1 PDGFRA PRKAR1A SOX10
18 vision/eye MP:0005391 9.23 GFAP KIT NF1 NF2 NGFR PRKAR1A

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Gentamicins Phase 4,Not Applicable
2 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
9
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
12
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
13
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
17 Hormones Phase 3
18 Antiemetics Phase 3
19 Anti-Inflammatory Agents Phase 3,Phase 2
20 Peripheral Nervous System Agents Phase 3,Phase 2
21 Methylprednisolone acetate Phase 3
22 Prednisolone acetate Phase 3
23 Gastrointestinal Agents Phase 3,Not Applicable
24 glucocorticoids Phase 3
25 Hormone Antagonists Phase 3
26 Protective Agents Phase 3,Phase 2
27 Autonomic Agents Phase 3
28 Neuroprotective Agents Phase 3
29
Isophosphamide mustard Phase 3,Phase 2 0
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
31 Alkylating Agents Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
34 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
35
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
36
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
38
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
39
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
40
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
41
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
47
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
50
Mesna Approved, Investigational Phase 2 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
7 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
8 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
9 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
13 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
16 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
18 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
19 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
20 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
21 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
22 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
23 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
24 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
25 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
26 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
27 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
28 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
29 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
30 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
31 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
32 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
33 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
34 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
35 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
36 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
37 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
38 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
39 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
40 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
41 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
42 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
43 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
44 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
45 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
46 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
47 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
48 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
49 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
50 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Genetic tests related to Neurilemmoma:

# Genetic test Affiliating Genes
1 Schwannoma 29

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

41
Tongue, Bone, Breast, Liver, Thyroid, Brain, Colon

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 1463)
# Title Authors Year
1
Tumor-to-Tumor Metastasis From a Breast Carcinoma to a Vestibular Schwannoma. ( 30531647 )
2019
2
Perioperative Recording of Cochlear Implant Evoked Brain Stem Responses After Removal of the Intralabyrinthine Portion of a Vestibular Schwannoma in a Patient with NF2. ( 30531638 )
2019
3
Benign diaphragmatic neurilemmoma mimicking a left adrenal cyst. ( 29484235 )
2018
4
A Rare Case of Primary Intrapulmonary Neurilemmoma Diagnosed in a 43-Year-Old Asymptomatic Man with a Well-defined Intrapulmonary Mass. ( 29441326 )
2018
5
Appendiceal schwannoma: a rare cause of perforated appendicitis. ( 30077983 )
2018
6
Spinal cellular schwannoma: An analysis of imaging manifestation and clinicopathological findings. ( 30017303 )
2018
7
MR imaging of vaginal cellular schwannoma. ( 30195699 )
2018
8
Successful Excision of Endobronchial Cellular Schwannoma with Right Lower Sleeve Lobectomy. ( 30205116 )
2018
9
De novo cavernous malformation arising in the wall of vestibular schwannoma following stereotactic radiosurgery: case report and review of the literature. ( 30430258 )
2018
10
Hypoglossal canal schwannoma causing isolated left 12th cranial nerve palsy. ( 30389733 )
2018
11
Extra-abdominal Desmoid Tumor Mimicking Cervical Spine Schwannoma. ( 30345202 )
2018
12
Unusual Delayed Presentation of Posterior Reversible Encephalopathy Syndrome Following Vestibular Schwannoma Surgery: A Rare Neurologic Emergency. ( 30261399 )
2018
13
Occipital lobe epilepsy was presented in a patient with intracerebral schwannoma: a case report and literature review. ( 30232919 )
2018
14
Gastric schwannoma-a rare benign mimic of gastrointestinal stromal tumor. ( 29564143 )
2018
15
Postoperative headache following treatment of vestibular schwannoma: A literature review. ( 29656878 )
2018
16
"Collateral Damage:" Horner's Syndrome Following Excision of a Cervical Vagal Schwannoma. ( 30123753 )
2018
17
Surgical management of retroperitoneal schwannoma complicated with severe hydronephrosis: A case report. ( 30278542 )
2018
18
Plexiform Schwannoma with Localized Hypertrichosis. ( 30065605 )
2018
19
Case of Lumbar Schwannoma Presenting with Isolated Signs and Symptoms of Intracranial Hypertension. ( 30096499 )
2018
20
Ileal schwannoma causing intussusception in an adult. ( 30381306 )
2018
21
Differentiation Between Intralabyrinthine Schwannoma and Contrast-enhancing Labyrinthitis on MRI: Quantitative Analysis of Signal Intensity Characteristics. ( 30020263 )
2018
22
Palisading and Verocay Body Prominent Orbital Leiomyosarcoma, Masquerading as a Schwannoma. ( 30326763 )
2018
23
Spontaneous Transformation of Vestibular Schwannoma into Malignant Peripheral Nerve Sheath Tumor. ( 30283553 )
2018
24
Duodenal Schwannoma as a Rare Association With Membranous Nephropathy: A Case Report. ( 30454884 )
2018
25
Unusual discovery of a vestibular schwannoma following eradication therapy for Mycobacterium abscessus. ( 30158267 )
2018
26
Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver. ( 30101901 )
2018
27
A rare combination of giant right retroperitoneal schwannoma and right adrenal oncocytoma as an incidental finding. ( 30397503 )
2018
28
Utility of intraoperative monitoring with motor-evoked potential during the surgical enucleation of peripheral nerve schwannoma. ( 29844829 )
2018
29
Analysis of Peripheral Nerve Schwannoma Pseudocapsule. ( 30114537 )
2018
30
Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders. ( 28737257 )
2018
31
Sudden-onset C8 Radiculopathy due to a Plexiform Schwannoma of the Cervical Nerve Root. ( 29984772 )
2018
32
Plexiform Schwannoma of the Tongue in a Pediatric Patient with Neurofibromatosis Type 2: A Case Report and Review of Literature. ( 30410810 )
2018
33
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer. ( 30371596 )
2018
34
Rarely Encountered, Seldom Considered: Posterior Tibial Nerve Schwannoma Mimicking Lumbar Radiculopathy. ( 29456371 )
2018
35
Presentation and Treatment of a Combined Median Nerve Schwannoma and a C7 Discogenic Radiculopathy. ( 30254799 )
2018
36
The prevalence of vestibular schwannoma among patients treated as sudden sensorineural hearing loss. ( 30042019 )
2018
37
Pediatric intramedullary schwannoma with syringomyelia: a case report and literature review. ( 30486806 )
2018
38
Schwannoma of the Posterior Tibial Nerve Presenting as Tarsal Tunnel Syndrome: A Case Report with Emphasis on the Role of Microscope during Surgery. ( 30155329 )
2018
39
Cerebral venous sinus thrombosis after vestibular schwannoma surgery: a call for evidence-based management guidelines. ( 29961375 )
2018
40
The tethered effect of vestibular schwannoma tumor shrinkage following stereotactic radiosurgery in secondary trigeminal neuralgia. ( 30553070 )
2018
41
Contralateral trigeminal neuralgia in a rapidly growing vestibular schwannoma: A case report. ( 29107410 )
2018
42
Microvascular Decompression for Treatment of Trigeminal Neuralgia in Patient with Facial Nerve Schwannoma. ( 29477001 )
2018
43
Giant intercostal nerve schwannoma in a patient with neurofibromatosis type 2. ( 29983103 )
2018
44
Bilateral Spontaneous Regression of Vestibular Schwannoma in Neurofibromatosis Type 2. ( 29477000 )
2018
45
Contralateral Hearing Loss After Resection of Vestibular Schwannoma in a Patient with Neurofibromatosis 2: Case Report and Literature Review. ( 29902600 )
2018
46
Cerebellopontine Angle Schwannoma and Meningioma in Contiguity: Surgical Implications in Neurofibromatosis. ( 29241266 )
2018
47
Stereotactic radiotherapy for presumed oculomotor nerve schwannoma masquerading as "ophthalmoplegic migraine". ( 30340730 )
2018
48
Malignant intercostal psammomatous melanotic schwannoma in a patient with Carney complex. ( 29132201 )
2018
49
Frontal lobe intracerebral schwannoma mimicking metastatic lesion in a patient with papillary thyroid carcinoma. ( 30151105 )
2018
50
Comparison of cervical vestibular evoked potentials evoked by air-conducted sound and bone-conducted vibration in vestibular Schwannoma patients. ( 30261801 )
2018

Variations for Neurilemmoma

ClinVar genetic disease variations for Neurilemmoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh38 Chromosome 22, 23834262: 23834262
2 SMARCB1 NM_003073.4(SMARCB1): c.*82C> T single nucleotide variant Pathogenic rs878854600 GRCh37 Chromosome 22, 24176449: 24176449

Copy number variations for Neurilemmoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ruffle GO:0001726 9.67 EZR NF2 S100B
2 apical part of cell GO:0045177 9.65 EZR MSN NF2
3 cell body GO:0044297 9.63 EZR GFAP NF2
4 intermediate filament GO:0005882 9.56 DES GFAP NES VIM
5 filopodium GO:0030175 9.54 EZR MSN NF2
6 uropod GO:0001931 9.51 EZR MSN
7 microvillus GO:0005902 9.5 EZR MSN PDGFRA
8 cytoplasm GO:0005737 9.47 DES ENO2 EZR GFAP KIT MSN
9 astrocyte projection GO:0097449 9.43 EZR GFAP
10 invadopodium GO:0071437 9.4 EZR MSN
11 intermediate filament cytoskeleton GO:0045111 9.33 DES GFAP NES
12 myelin sheath GO:0043209 9.26 ENO2 EZR GFAP MSN

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 EZR KIT MSN SOX10 VIM
2 central nervous system development GO:0007417 9.76 NES S100B SOX10
3 negative regulation of protein kinase activity GO:0006469 9.69 NF1 NF2 PRKAR1A
4 negative regulation of neuron projection development GO:0010977 9.61 GFAP NGFR VIM
5 melanocyte differentiation GO:0030318 9.59 KIT SOX10
6 astrocyte development GO:0014002 9.58 GFAP VIM
7 establishment of endothelial barrier GO:0061028 9.57 EZR MSN
8 establishment of epithelial cell apical/basal polarity GO:0045198 9.56 EZR MSN
9 positive regulation of cellular protein catabolic process GO:1903364 9.55 EZR MSN
10 positive regulation of myelination GO:0031643 9.54 S100B SOX10
11 positive regulation of phospholipase C activity GO:0010863 9.52 KIT PDGFRA
12 gland morphogenesis GO:0022612 9.49 EZR MSN
13 Bergmann glial cell differentiation GO:0060020 9.48 GFAP VIM
14 positive regulation of early endosome to late endosome transport GO:2000643 9.46 EZR MSN
15 regulation of cell shape GO:0008360 9.46 EZR KIT MSN S100B
16 positive regulation of protein localization to early endosome GO:1902966 9.4 EZR MSN
17 membrane to membrane docking GO:0022614 9.32 EZR MSN
18 regulation of organelle assembly GO:1902115 9.26 EZR MSN
19 intermediate filament-based process GO:0045103 8.96 GFAP VIM
20 intermediate filament organization GO:0045109 8.8 DES GFAP VIM

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.73 DES EZR GFAP S100B SOX10 VIM
2 S100 protein binding GO:0044548 9.37 EZR S100B
3 protein kinase A catalytic subunit binding GO:0034236 9.32 EZR PRKAR1A
4 structural constituent of cytoskeleton GO:0005200 9.26 DES GFAP MSN VIM
5 cytoskeletal protein binding GO:0008092 8.92 DES EZR MSN NF2
6 protein binding GO:0005515 10.03 DES ENO2 EZR GFAP KIT MSN

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....